Tag:
Bayer
Latest Headlines
Latest Headlines
Novartis' Jimenez says no need to sell Roche stake
With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
Data, schmata. Doctors want to feel pharma, too
Harris Interactive has been digging into physicians' response to drug brands, therapeutic area by therapeutic area, racking up more evidence for an emotional variable in the doctor-drug trust equation.
Clot-fighter Eliquis wins speedy new backing from NICE
The U.K.'s cost-effectiveness watchdogs must really like Eliquis. The new blood thinner from Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) won a thumbs-up for stroke prevention.
Bayer gains FDA nod for long-use IUD
For the first time in 12 years, the U.S. has a new IUD approved for commercial use, and Bayer is bringing it to market in early February.
Swiss insurer jumps into legal fight over Bayer's Yasmin
Bayer has another foe in its battle to defend the contraceptive pill Yasmin. Switzerland's biggest insurer, CSS, is backing a woman's claims against the German company, joining in her lawsuit that alleges Yasmin triggered her disabling pulmonary embolism.
Lucentis nears final NICE nod for diabetes-related vision loss
Novartis is one step closer to marketing Lucentis in a new group of patients. The National Institute for Health and Clinical Excellence officially changed its mind on the Swiss drugmaker's eye treatment, recommending the pricey injection for use in diabetics.
Worried about blood clots, France weighs new contraceptive limits
French regulators are tightening the purse strings on later-generation contraceptives--and studying limits on their use. Acting on concerns that the pills carry a higher risk of blood clots than older birth-control brands, the country's health ministry will stop paying for third-generation pills beginning March 31.
WSJ: Pfizer animal health IPO could happen next month
Pfizer's animal health unit may be worth $20 billion, and that is the conundrum.
Report: Sanofi considering Bayer's glucose meter unit
After sources said Bayer was halting its blood glucose meter sale, The Wall Street Journal reports that Sanofi remains in talks with the German company over a deal that could be worth about $1.5 billion.
EU green-lights Bayer's Jaydess hormone IUS
European regulators have given the thumbs-up to Bayer's Jaydess, a low-dose controlled-release hormonal contraceptive.
